Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications

Urology

Volumn 54, Issue 1, 1999, Pages 81-85

  Lowe, Franklin C ^a   Olson, Peggy J ^a   Padley, Robert J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; TERAZOSIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BLOOD PRESSURE; HUMANS; HYPERTENSION; MALE; PRAZOSIN; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES;

EID: 0033168361     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00057-6     Document Type: Article

References (17)

1. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: Sixth Report (JNC VI). Arch Intern Med 157: 2413-2446, 1997.
2. Napalkov P, Maisonneuve P, and Boyle P: Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 46: 41-46, 1995.
3. Boyle P: Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension. Br J Clin Pract Suppl 74: 18-22, 1994.
4. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: Filth Report (JNC V). Arch Intern Med 154: 154-183, 1993.
5. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition examination survey, 1988-1991. JAMA 274: 1254, 1995.
6. Boyle P, and Naplikov P: The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 29: 7-12, 1995.
7. Burt VL, Whelton P, and Rocella EJ: Prevalence of hypertension in the US adult population. Results from the third National Health and Nutrition examination survey, 1988-1991. Hypertension 25: 305-313, 1995.
8. Shapiro E, Hartano V, and Lepor H: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 21: 297-307, 1992.
9. Nieble JP, and Ruffolo RR: The use of alpha-receptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res 33: 145-160, 1996.
10. Guthrie R: Terazosin in the treatment of benign prostatic hyperplasia: a primary care trial. J Earn Pract 39: 129-133, 1994.
11. Lowe EC: Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 44: 46-51, 1994.
12. McKiernan JM, and Lowe EC: Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South J Med 90: 509-513, 1997.
13. Kaplan SA, and Kaplan NM: Alpha-blockade for hypertension and benign prostatic hyperplasia. Urology 48: 541-560, 1996.
14. Lepor H, Kaplan SA, Klimberg I, et al: Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 157: 525-530, 1997.
15. Gillenwater JY, Conn RL, Chrysant SG, et al: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo controlled, dose-response multicenter study. J Urol 154: 110-115, 1995.
16. Kirby RS: Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 46: 182-186, 1995.
17. Roehrborn CG, Oesterling JE, Auerbach S, et al: The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with benign prostatic hyperplasia. Urology 47: 159-168, 1996.